Efficacy and safety of intraperitoneal bevacizumab combined with hyperthermic intraperitoneal chemotherapy in the treatment of patients with ovarian cancer and peritoneal effusion and the effect on serum lncRNA H19 and VEGF levels

Meiling Zhanga The Second Department of Oncology, Huoshan County Hospital, Huoshan County, Lu’an City, Anhui Province, P.R. China

Yu Baob Department of Oncology, The People’s Hospital of Chizhou, Chizou City, Anhui Province, P.R. China

Hong Zhangc Department of Oncology, Hefei City, Anhui Province, P.R. ChinaAnhui No.2 People’s Hospital, No. 1868 Dangshan Road, Yaohai District

Dongmei Lid Department of Oncology, Taihe County Hospital of Traditional Chinese Medicine, Taihe County, Fuyang City, Anhui Province, P.R. China

Xinkuan Meie Department of Medical Oncology, Fuyang Cancer Hospital, Fuyang City, Anhui Province, Yingzhou District, P.R. China

Xianping Chengc Department of Oncology, Hefei City, Anhui Province, P.R. ChinaAnhui No.2 People’s Hospital, No. 1868 Dangshan Road, Yaohai DistrictCorrespondence[email protected]

Efficacy and safety of intraperitoneal bevacizumab combined with hyperthermic intraperitoneal chemotherapy in the treatment of patients with ovarian cancer and peritoneal effusion and the effect on serum lncRNA H19 and VEGF levels

Supplemental Material

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Efficacy and safety of intraperitoneal bevacizumab combined with hyperthermic intraperitoneal chemotherapy in the treatment of patients with ovarian cancer and peritoneal effusion and the effect on serum lncRNA H19 and VEGF levels

Supplemental Material

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date